According to the most recent official data, India has recorded 9,283 new coronavirus cases and 437 linked fatalities in the last 24 hours. The number of active cases was 1,11,481, accounting for 1% of the total number of cases, the lowest since March 2020. The recovery rate was at 98.33 percent, the highest since the beginning of the year.
Meanwhile, according to the first real-world assessment of India’s indigenous COVID-19 vaccine published in The Lancet Infectious Diseases journal, two doses of Covaxin are 50% effective against symptomatic disease.
Two doses of Covaxin, also known as BBV152, were found to have 77.8% efficacy against symptomatic illness in an interim study just published in The Lancet, with no major safety concerns.
From April 15 to May 15, 2,714 hospital personnel were screened at the All India Institute of Medical Sciences (AIIMS) in Delhi, who were symptomatic and completed a COVID-19 RT-PCR test.
The Delta variety was the most common strain in India throughout the study period, accounting for over 80% of all confirmed COVID-19 cases, according to the researchers.
